Olympus Corporation
http://www.olympus.co.jp
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Olympus Corporation
Tech Transfer Roundup: Athenex, PDS Align With National Cancer Institute On Oncology R&D
Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.
Minute Insight: Olympus Corporation Joins VC Race With Its Own Fund
The Japanese company is hoping to access breaking technologies sooner via earlier investment.
Finance Watch: Biotech Venture Capital Had Its Biggest Quarter Ever
Private Company Edition: VC mega-rounds boosted the Q1 2021 total. Also, new funds from Versant, The Column Group and Rapha Capital keep cash flowing into biopharma; up to $525m is invested in Exscientia; and Arch Oncology and Boundless Bio raised $105m each, while Forge brought in $120m.
Market Brief: Global Market For Arthroscopy And Sports Medicine Products Will Reach $6.3Bn By 2025
The global market for arthroscopy products and sports medicine implants is expected to reach $6.3bn by 2025, a CAGR of 1.9% from $5.7bn in 2020. The growth is driven partly by rising arthroscopy procedure volumes, expanding indications for joint repair, and patient preference for minimally invasive procedures. COVID-19 and downward pressures on device prices are among the growth barriers.
Company Information
- Industry
- Medical Devices
-
Medical Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
-
Surgical Equipment & Devices
- Other Names / Subsidiaries
-
- ARC Medical Design Ltd
- Gyrus Group PLC
- Image stream Medical, Inc.
- Olympus Biotech
- Olympus Optical Co., Ltd.
- Olympus Surgical America
- Spiration Inc.
- Quest Innovations B.V.
- Veran Medical Technologies, Inc.